Cancer Cachexia Drugs
Jan 16, 2026
Cancer Cachexia Drug Landscape Heats Up with Multiple Assets Advancing—7 Therapies to Watch Out
Summary Cancer cachexia is a severe, multifactorial wasting syndrome affecting most advanced cancer patients, with no approved therapies in the US or Europe and only ADLUMIZ approved in Japan, underscoring a major unmet need. Despite the historical treatment gap, the cancer cachexia pipeline is now rapidly e...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
